Rizzieri, D. A., Koh, L. P., Long, G. D., Lagoo, A. S., Gasparatto, C., Vredenburgh, J. J., … Chao, N. J. (2003). Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy from HLA matched siblings. In BLOOD (Vol. 102, pp. 238A-239A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.

Rizzieri, D. A., L. P. Koh, G. D. Long, A. S. Lagoo, C. Gasparatto, J. J. Vredenburgh, P. J. Buckley, et al. “Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy from HLA matched siblings.” In BLOOD, 102:238A-239A. AMER SOC HEMATOLOGY, 2003.

Rizzieri DA, Koh LP, Long GD, Lagoo AS, Gasparatto C, Vredenburgh JJ, et al. Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy from HLA matched siblings. In: BLOOD. AMER SOC HEMATOLOGY; 2003. p. 238A-239A.

Rizzieri, D. A., et al. “Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy from HLA matched siblings.” BLOOD, vol. 102, no. 11, AMER SOC HEMATOLOGY, 2003, pp. 238A-239A.

Rizzieri DA, Koh LP, Long GD, Lagoo AS, Gasparatto C, Vredenburgh JJ, Buckley PJ, Gong G, Loftis J, Rowe K, Rooney B, Niedzweicki D, Waters-Pick B, Eren P, Vujevich D, Catlin C, Folz RJ, Sullivan K, Horwitz ME, Morris A, Chao NJ. Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy from HLA matched siblings. BLOOD. AMER SOC HEMATOLOGY; 2003. p. 238A-239A.